2013 Targeting Trends Review

Mavrogenis AF, Pavlakis K, Stamatoukou A, Papagelopoulos PJ, Theoharis S, Zetahang Z, Soucacos PN, Zoubos AB (2013) Intraneural OX7-saporin for neuroma-in-continuity in a rat model. Eur J Orthop Surg Traumatol 23(3):263-272. doi: 10.1007/s00590-012-0996-x

Summary: The authors created a model of neuroma-in-continuity to explore the effect of OX7-SAP (Cat. #IT-02) on the neuroma. The left common peroneal, tibial or sciatic nerves were crushed, then at three and six weeks, the nerve cut distal to the site of nerve crush. Pressure microinjection of 2 μl of natural saline or 2 μl of the OX7-SAP was done at the nerve stump 2 days later. Sacrifice was done after 3 weeks. In all control specimens a neuroma-in-continuity was observed. In 19 of the 24 OX7-SAP specimens, histology showed inhibition of neuroma-in-continuity formation.

Related Products: OX7-SAP (Cat. #IT-02)

Lin LH, Nitschke Dragon D, Talman WT (2012) Collateral damage and compensatory changes after injection of a toxin targeting neurons with the neurokinin-1 receptor in the nucleus tractus solitarii of rat. J Chem Neuroanat 43(2):141-148. doi: 10.1016/j.jchemneu.2012.02.001

Summary: Loss of substance P receptor (SPR)-expressing neurons in the nucleus tractus solitarii (NTS) results in reduced baroreflex strength and unstable arterial pressure. The neuronal population expressing the SPR also expresses several other types of receptors – such as N-methyl-D-aspartate (NMDA), and aalpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic (AMPA) receptors. The authors administered 9 ng of SSP-SAP (Cat. #IT-11) into the NTS and looked for differences in the expression of NMDA and AMPA receptors, as well as several different transporters and neuronal markers. he data suggest that the pathological effects of SSP-SAP lesions result from disruption of other neurotransmission systems than those using the SPR.

Related Products: SSP-SAP (Cat. #IT-11)